An experimental treatment happens to be the solution to delay Alzheimer's symptoms in some people. These people are the ones who are genetically destined to get the disease in their 40s or 50s. These new findings form ongoing research has now been caught up in Trump administration funding delas. The early results of the study has been published on Wednesday and the participants too are worried that politics could cut their access to a possible lifeline.

One of the participants had said, "It is still a study but it has given me an extension to my life that I never banked on having." The participant is named Jake Henrichs, form New York City, who is 50 years old. He is one of them to be treated in that study for more than a decade now and has remained symptom-free despite inheriting an Alzheimer's-causing gene that had killed his father and brother around the same age.

Slowing Down The Symptoms

Two drugs which can modestly slow down early-stage Alzheimer's are sold in the United States. These drugs clear the brain of one of its hallmarks, a sticky gunk-like part called the amyloid. However, there have not been any hints that removing amyloid far earlier, way many years before the first symptoms appear, may postpone the disease.

How Was The Research Conducted?

The research is led by Washington University in St Louis, which involved families that passed down rare gene mutation as participants. This meant it was almost guaranteed that they will develop symptoms at the same age their affected relatives did.

The new findings is based on a subset of 22 participants who received amyloid-removing drugs the longest, on average eight years. Long-term amyloid removal cut in half their risk of symptom onset. The study is published in the journal Lancet Neurology.

Washington University's Dr Randall Bateman, who directs the Dominantly Inherited Alzheimer's Network of studies involving families with these rare genes says, "What we want to determine over the next five years is how strong is the protection. Will they ever get the symptoms of Alzheimer’s disease if we keep treating them?”

The researchers before though did not know what exactly caused Alzheimer's which affects nearly 7 million Americans, most of them in their later life. However, it is clear that these silent changes occur in the brain at least two decades before the first symptom shows up. The big contributor. At some point amyloid buildup can trigger a protein named tau that then starts to kill neurons, which can lead to cognitive decline.

Researchers are now thus studying the Tau-fighting drugs and are looking into other factors, like inflammation, brain's immune cells and certain virus.

The National Institute of Health (NIH) has expanded its focus as researchers have found more reasons for Alzheimer's. In 2013, the NIH's National Institute on Aging funded 14 trials of possible Alzheimer's drugs over a third targeting amyloid. By last fall, there were 68 drugs and 18% of them target amyloid. However, there are scientists too who think that amyloid is not everything and their is way more in the brain tissue, immune cells, and more which can be studied.

Teen mental health in the US is improving, with fewer high school students reporting persistent sadness or hopelessness, poor mental health and suicidal thoughts, according to new data from the Centers for Disease Control and Prevention (CDC).

The CDC’s Youth Risk Behavior Survey (YRBS), conducted among high school students nationwide in 2025, provides data on youth mental health, physical activity, sleep, diet and digital behaviors. The latest report includes national data from 2023 to 2025 and 10-year trends from 2015 to 2025.

Teen Mental Health Shows Improvement

Several mental health and suicide risk indicators improved between 2023 and 2025:

• Persistent sadness or hopelessness fell from 40% to 33%.
• Poor mental health declined from 29% to 23%.
• Seriously considering suicide fell from 20% to 14%.

Also read: More COVID Infections, More Health Problems? Back, Respiratory, Mental Problems Among New Risks

"These are meaningful improvements, and they show that progress is possible when schools, families, and communities work together to support young people," said Dr. Jennifer Shuford, CDC's deputy director and chief medical officer.

At the same time, the data showed that many teenagers, especially girls and teenagers who identify as lesbian, gay or bisexual, are still struggling.

Thirty-three percent of high school students reported persistent feelings of sadness or hopelessness in the last 12 months, down from a peak of 42 percent in 2021.

Fourteen percent of teenagers reported that they had seriously considered attempting suicide, down from 22 percent in 2021.

“Those declines in depression and suicidal thoughts are very striking, particularly that they’re lower than 2019,” said Jean Twenge, a psychologist at San Diego State University who has studied the mental health impacts of smartphones and social media use on teenagers, NYT reported.

“This isn’t just post-pandemic anymore; this is a more longstanding trend in improvement,” Twenge added.

Diet And Sports Participation Improve

Some healthy behaviors also improved between 2023 and 2025:

• Daily fruit consumption rose from 33% to 39%.
• Daily vegetable consumption increased from 58% to 63%.
• The percentage of students drinking plain water at least three times a day rose from 54% to 58%.
• Sports team participation increased from 52% to 58%.

However, daily physical activity, muscle-strengthening activity and meeting recommended activity guidelines remained unchanged.

Read More: From Remdesivir To Ventilators: COVID Patients Died Due To Hospital Protocols, Claims Whistleblower Nurse

Most Teens Still Don't Get Enough Sleep

Only 24% of students reported getting at least eight hours of sleep on an average school night in 2025, similar to 23% in 2023.

Insufficient sleep is linked to poor mental health, difficulty concentrating and risky behaviors.

Social Media Use Remains High

About 36% of students reported using social media every hour or more in 2025, similar to 37% in 2023.

Among students who drove in the previous month, 46% reported texting or emailing while driving, up from 42% in 2023.

The CDC noted that digital behaviors can affect sleep, physical activity, nutrition, safety and mental well-being.

The Youth Risk Behavior Survey has been conducted every two years since 1991 and provides nationally representative data to help identify emerging health challenges and track long-term trends.

NHS England has announced the expansion of Martha’s Rule to all hospital emergency departments and waiting rooms in England to help patients, families and staff raise concerns about worsening conditions.

Martha’s Rule was introduced following the death of 13-year-old Martha Mills and mandated at acute inpatient sites in 2025. Its expansion to A&Es will be phased in and completed by March 2028.

“A&Es see some of our most vulnerable patients, so the ability to raise concerns about deterioration quickly and trigger a rapid review of care is essential,” said Professor Aidan Fowler, National Director of Patient Safety at NHS England.

“Martha’s Rule is already having a transformative effect in making our acute care even safer, and by expanding Martha’s Rule into A&Es, we are giving even more patients, their families and NHS staff a critical new lifeline to help improve care and save more lives,” he added.

How Will Martha’s Rule Work In A&E?

Also read: UK Flu Jabs Begin For Children And Pregnant Women: What You Need To Know

An NHS England pilot, conducted between September 2025 and March 2026, found that Martha’s Rule could work alongside existing emergency-care procedures to identify early signs of deterioration without requiring additional clinical staff.

During the pilot, 69 calls were made to dedicated Martha’s Rule numbers. Some resulted in urgent surgery or transfer to intensive care.

“Martha’s Rule is about making sure patients and their loved ones are heard when they raise concerns about their care,” said Health and Social Care Minister Baroness Merron.

“Expanding it to A&E will give patients, families and staff another way to speak up when they are worried that someone’s condition is getting worse, ensuring concerns are acted on quickly,” Merron added.

Who Was Martha Mills?

Martha’s Rule is named after 13-year-old Martha Mills, who developed sepsis while being treated at King’s College Hospital NHS Foundation Trust in south London in 2021 and later died.

Her parents repeatedly raised concerns about her worsening condition. An investigation later found that Martha might have survived if signs of deterioration had been recognized and she had been transferred to intensive care.

Her parents subsequently campaigned for a formal system allowing patients and families to raise concerns and seek an urgent clinical review.

How Does Martha’s Rule Work?

The rule has three main components:

• Patients are asked daily how they are feeling, with responses recorded.
• Staff can request an urgent review from another team if they are concerned about a patient.
• Patients, families and caregivers can also request an urgent review if they are worried about a worsening condition.

Hospitals provide a dedicated number that patients and families can use to request a rapid review by a different team when concerns are not being addressed.

Has Martha’s Rule Saved Lives?

In July 2026, 1,678 calls were made through Martha’s Rule — the highest monthly total so far.

More than 19,000 calls (19,177) were made by patients, families and NHS staff between September 2024 and July 2026.

The rule has been rolled out at 221 acute adult and pediatric inpatient sites, with the current rollout expected to be completed in 2026/27.

It is also being extended to A&E, maternity and neonatal units, with the wider rollout due to be completed by March 2028.

Novo Nordisk's next-generation obesity drug CagriSema has delivered greater weight loss than a lower dose of Eli Lilly's tirzepatide in a new late-stage trial. The trial has given giving the Danish drugmaker new evidence for its upcoming weight loss injectable as it competes in the rapidly expanding GLP-1 obesity drug market.

In the Phase 3 REIMAGINE 5 trial, adults with type 2 diabetes receiving CagriSema lost an estimated 12.4% of their body weight after 60 weeks, compared with 9.1% among those receiving 5 mg of tirzepatide, the active ingredient in Lilly's Mounjaro and Zepbound. CagriSema also resulted reduction in HbA1c, a measure of average blood sugar.

However, the trial compared 1 mg/1 mg CagriSema to 5 mg tirzepatide, rather than the highest doses used in obesity treatment. Earlier this year, a separate Phase 3 trial in people with obesity found that CagriSema did not meet its goal against high-dose 15 mg tirzepatide. At 84 weeks, CagriSema resulted in 23% weight loss compared to 25.5% with tirzepatide.

What Is CagriSema?

CagriSema is a once-weekly injection that combines two active ingredients: semaglutide and cagrilintide.

Semaglutide is the active ingredient in Novo's Wegovy and Ozempic. It belongs to the GLP-1 receptor agonist class and helps reduce appetite and food intake. Cagrilintide mimics amylin, a hormone involved in appetite regulation and feelings of fullness. By combining the two medicines, Novo is attempting to produce greater weight loss results.

Unlike Wegovy and Ozempic, however, CagriSema is still investigational. Novo submitted it to the US FDA for weight management in December 2025. The regulatory decision is expected in the fourth quarter of 2026.

Also read: Hundreds Of American GLP-1 Users Sue Novo Nordisk, Eli Lilly Over Vision Loss: What Is NAION?

What Did The New Trial Find?

REIMAGINE 5 is based on adults with type 2 diabetes whose blood sugar was not controlled properly with metformin, an SGLT2 inhibitor or both. After 60 weeks, CagriSema showed 12.4% average weight loss. Tirzepatide 5 mg resulted in 9.1% average weight loss.

CagriSema showed 1.71% HbA1c reduction while tirzepatide resulted in 1.67%.

Novo said the combination was generally well tolerated. Gastrointestinal side effects are among the common adverse effects that were seen with the treatment.

Novo's chief scientific officer Martin Holst Lange called the findings “very encouraging” and said they strengthen the company's confidence in CagriSema's potential.

Also read: Blood Test That Could Detect 50+ Cancers Closer To Approval As FDA Raises No Major Concerns About Its Accuracy

Is CagriSema Better Than Mounjaro Or Zepbound?

The new study establishes that CagriSema outperformed 5 mg tirzepatide for weight loss in this particular population sample with type 2 diabetes.

But tirzepatide is available at substantially higher doses, and the earlier obesity head-to-head trial compared CagriSema with 15 mg tirzepatide, where tirzepatide produced better weight loss results.

Therefore, the company has not declared that CagriSema consistently produces more weight loss than tirzepatide across all trials.

CagriSema is Novo's attempt to move beyond single-pathway GLP-1 treatment by combining GLP-1 and amylin biology. In another new Phase 3 trial, REDEFINE 9, CagriSema produced 21% weight loss after 68 weeks, compared with 2% with placebo, in adults with overweight or obesity.